Hazard Score Can Estimate Age of Prostate Cancer Diagnosis

Share this content:
Hazard Score Can Estimate Age of Prostate Cancer Diagnosis
Hazard Score Can Estimate Age of Prostate Cancer Diagnosis

THURSDAY, Jan. 11, 2018 (HealthDay News) -- A hazard score calculated from 54 single nucleotide polymorphisms can predict age at diagnosis of aggressive prostate cancer (PCa), according to a study published online Jan. 10 in The BMJ.

Tyler M. Seibert, M.D., from the University of California, San Diego, in La Jolla, and colleagues developed and validated a genetic tool to predict age of onset of aggressive PCa. Single nucleotide polymorphisms associated with diagnosis were selected in analysis of genotype, PCa status, and age. To estimate their effects on age at diagnosis of aggressive PCa, these polymorphisms were incorporated into a survival analysis. The development and validation datasets comprised 31,747 and 6,411 men, respectively.

The researchers found that the hazard score calculated from 54 single nucleotide polymorphisms significantly predicted age at diagnosis of aggressive cancer in the independent validation set. The hazard ratio for aggressive cancer was 2.9 when comparing men in the validation set with high scores (>98th centile) to those with average scores (30 to 70th centile). Prediction of onset of aggressive PCa was not improved by inclusion of family history in a combined model; when family history was accounted for, polygenic hazard score performance remained high. With increasing polygenic hazard score, the positive predictive value of prostate-specific antigen screening for aggressive PCa was increased.

"Polygenic hazard scores can be used for personalized genetic risk estimates that can predict for age at onset of aggressive PCa," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical technology industries.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »